BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38128340)

  • 1. Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies.
    Gorji L; Brown ZJ; Pawlik TM
    Surg Oncol; 2024 Feb; 52():102031. PubMed ID: 38128340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
    Argemi J; Ponz-Sarvise M; Sangro B
    Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].
    Voesch S; Bitzer M; Malek N
    Radiologe; 2022 Mar; 62(3):200-204. PubMed ID: 35147708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.
    Wan S; Zhao E; Weissinger D; Krantz BA; Werba G; Freeman D; Khanna LG; Siolas D; Oberstein PE; Chattopadhyay PK; Simeone DM; Welling TH
    Front Immunol; 2023; 14():1067352. PubMed ID: 36798126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
    Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
    Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
    Cheng K; Cai N; Zhu J; Yang X; Liang H; Zhang W
    Cancer Commun (Lond); 2022 Nov; 42(11):1112-1140. PubMed ID: 36069342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Functional Roles of Immune Cells in Primary Liver Cancer.
    Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
    Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in cholangiocarcinoma.
    Al-Rajabi R; Sun W
    Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.
    Polidoro MA; Mikulak J; Cazzetta V; Lleo A; Mavilio D; Torzilli G; Donadon M
    World J Gastroenterol; 2020 Sep; 26(33):4900-4918. PubMed ID: 32952338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma and cholangiocarcinoma: an update.
    Yazici C; Niemeyer DJ; Iannitti DA; Russo MW
    Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):63-82. PubMed ID: 24245910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.